Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2149, known as LINC02149, is a member of the lincRNA class of RNA molecules, which are defined as autonomously transcribed non-coding RNAs longer than 200 nucleotides that do not overlap annotated coding genes [1][5]. Like other lincRNAs, LINC02149 is not translated into protein and may play roles in the regulation of gene expression, either by influencing chromatin structure, modulating transcription, or interacting with protein or RNA partners[5]. At present, there are no documented therapeutic agents, validated direct disease associations, or established functions specific to LINC02149 in the provided literature or major genic databases, though the broad lincRNA class contributes to gene expression regulation and potentially to disease[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2149 (LINC02149).